Altamira Therapeutics Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Selling, General & Admin	3.14	3.4	3.67	2.59	3.93	4.26	5.15	5.45	4.34	4.49	Upgrade
Research & Development	3.04	14.62	3.2	2.86	3.33	6.69	19.21	24.78	26.54	17.7	Upgrade
Other Operating Expenses	-0.26	-0.01	0	0.05	0	0.52	1.03	0	0	0	Upgrade
Operating Expenses	5.92	18.01	6.87	5.5	7.26	11.47	25.39	30.22	30.88	22.19	Upgrade
Operating Income	-5.92	-18.01	-6.87	-5.5	-7.26	-11.47	-25.39	-30.22	-30.88	-22.19	Upgrade
Interest Expense / Income	1.67	1.21	0.01	0.14	0.03	1.07	1.64	0.83	0.01	0.06	Upgrade
Other Expense / Income	-3.72	7.31	10.29	2.58	-0.46	-1.21	-2.6	-0.26	-1.18	-4.06	Upgrade
Pretax Income	-3.87	-26.54	-17.18	-8.22	-6.83	-11.33	-24.43	-30.79	-29.71	-18.19	Upgrade
Income Tax	0	-0.01	-0.12	-0.02	-0.19	0.16	-0.02	-0.13	0	0	Upgrade
Net Income	-3.87	-26.53	-17.06	-8.2	-6.63	-11.5	-24.41	-30.66	-29.71	-18.19	Upgrade
Shares Outstanding (Basic)	0	0	0	0	0	0	0	0	0	0	Upgrade
Shares Outstanding (Diluted)	-	-	-	-	-	-	-	-	0	0	Upgrade
Shares Change	832.23%	25.08%	169.67%	169.85%	674.71%	41.03%	-	6.19%	16.76%	-	Upgrade
EPS (Basic)	-7.88	-582.58	-515.11	-505.40	-45.60	-5784.00	-44644.00	-71440.00	-73600.00	-52800.00	Upgrade
EPS (Diluted)	-7.88	-582.58	-515.11	-505.40	-45.60	-5784.00	-44644.00	-71440.00	-73600.00	-52800.00	Upgrade
Free Cash Flow	-11.51	-8.68	-13.67	-4.84	-8.46	-13.16	-24.28	-29.7	-28.81	-19.43	Upgrade
Free Cash Flow Per Share	-28.94	-203.54	-400.87	-382.95	-1804.37	-21770.42	-56585.80	-69258.40	-71350.54	-56129.41	Upgrade
EBITDA	-2.08	-25.21	-17.09	-8.07	-6.77	-10.19	-22.66	-29.87	-29.6	-18.06	Upgrade
Depreciation & Amortization	0.12	0.12	0.08	0.02	0.03	0.07	0.12	0.1	0.09	0.07	Upgrade
EBIT	-2.2	-25.33	-17.16	-8.09	-6.8	-10.26	-22.79	-29.96	-29.7	-18.13	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).